Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Brexit and the Impact to Your Global Business Operations: What Life Sciences Companies Need to Know Now Webinar, Nov. 1, 2018

FDANEWS
Posted on: 18 Oct 18
Brexit and the Impact to Your Global Business Operations: What Life Sciences Companies Need to Know Now Webinar, Nov. 1, 2018 The EMA thinks that Brexit may disrupt drug approvals and safety inspections for two to three years. What does that mean for drug and devicemakers?

PR Newswire

FALLS CHURCH, Va., Oct. 18, 2018

FALLS CHURCH, Va., Oct. 18, 2018 /PRNewswire-PRWeb/ -- Brexit and the Impact to Your Global Business Operations:
What Life Sciences Companies Need to Know Now
**An FDAnews Webinar**
Nov. 1, 2018 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/brexitimpactglblbusops

When Britain exits the EU, what happens?

The EMA is moving to from London to Amsterdam in March 2019 and will lose 30 percent of its staff. The agency has already stopped accepting and publishing clinical trials data.

What about the legal uncertainty regarding contracts involving both the UK and other EU member states?

Brexit is about to happen and drug and devicemakers need to make plans before it does. Prepare to discover:

  • The impact on international harmonization efforts: The EMA will "only take a reactive role," focus on "urgent" drug safety guidelines and limit travel to "Brexit-related interactions."
  • How to deal with the legal uncertainty introduced into contracts involving both the UK and EU member states
  • And much more…

Brexit will be finalized on March 29, 2019. Manufacturers need to know how it will impact their global operations. Register today to minimize potential disruptions.

Meet the Presenter
Michael Burke, Partner, Corporate Practice, Arnall Golden Gregory

Michael Burke provides practical and actionable legal and compliance guidance that allows companies to focus on business growth. He helps companies minimize risk and maximize return across a wide range of domestic and cross-border corporate and commercial transactions and regulatory issues. Mike is a partner in the Corporate Practice and co-chairs Arnall Golden Gregory's Pharmaceuticals and Medical Devices Industry Team. Mike co-chairs the American Bar Association-United Nations Development Programme International Legal Resource Center and is the immediate past chair of the American Bar Association's Section Officer's Conference.

Who Will Benefit
Any quality or regulatory professional at a life sciences company with operations involving the European Union and the United Kingdom including:

  • President
  • Vice President
  • Operations Managers
  • Supplier Managers
  • Regulatory Affairs
  • Quality Assurance

Webinar Details:
Brexit and the Impact to Your Global Business Operations:
What Life Sciences Companies Need to Know Now
**An FDAnews Webinar**
Nov. 1, 2018 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/brexitimpactglblbusops

Tuition:
$287 per site

Easy Ways to Register:
Online:     http://www.fdanews.com/brexitimpactglblbusops                            
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

 

SOURCE FDANEWS

PR Newswire
www.prnewswire.com

Last updated on: 18/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.